10.3 Treatment and Management of Schizophrenia

Pharmacological Treatments and Psychosocial Interventions

Treating schizophrenia requires both medication and therapy working together. Antipsychotics manage the brain chemistry side, while psychosocial interventions help patients build the skills and support systems they need to function day to day. Neither approach works as well on its own.

Pharmacological treatments for schizophrenia

Antipsychotic medications are the foundation of schizophrenia treatment. They work by altering neurotransmitter activity in the brain, and they fall into two main classes.

Typical (first-generation) antipsychotics block dopamine $D_2$ receptors. Examples include chlorpromazine and haloperidol.

• Effective at reducing positive symptoms like hallucinations and delusions
• Higher risk of extrapyramidal side effects (EPS), which are movement-related problems such as muscle stiffness, tremors, and restlessness
• Long-term use carries risk of tardive dyskinesia, a condition involving involuntary, repetitive movements (often of the face and tongue) that can be irreversible

Atypical (second-generation) antipsychotics block both dopamine and serotonin receptors. Examples include risperidone, olanzapine, quetiapine, and aripiprazole.

• Effective at reducing both positive and negative symptoms (like flat affect, social withdrawal, and lack of motivation)
• Lower risk of EPS compared to first-generation drugs
• Can cause metabolic side effects including significant weight gain, elevated blood sugar, and increased risk of type 2 diabetes

Antipsychotics are sometimes prescribed alongside other medications, such as mood stabilizers or antidepressants, when patients have co-occurring symptoms like depression or mood instability.

Psychosocial interventions in schizophrenia management

Medication alone doesn't address the full picture. Psychosocial interventions target the functional and social difficulties that often persist even when psychotic symptoms are controlled.

Cognitive-behavioral therapy (CBT) helps patients identify and challenge distorted thoughts and beliefs. For example, a patient who believes neighbors are spying on them can learn to evaluate that belief against evidence. CBT also teaches coping strategies for managing residual symptoms and can be delivered individually or in group settings.

Family psychoeducation educates family members about schizophrenia, its symptoms, and its treatment. This improves communication and problem-solving within the family, reduces caregiver stress and burden, and is consistently linked to better patient outcomes, including lower relapse rates.

Other key psychosocial interventions include:

• Social skills training helps patients develop and practice interpersonal skills like starting conversations, reading social cues, and maintaining relationships
• Vocational rehabilitation assists patients in finding and keeping employment, which supports both financial independence and a sense of purpose
• Assertive community treatment (ACT) provides intensive, team-based care in the community rather than in a hospital. ACT teams typically include psychiatrists, social workers, and nurses who coordinate all aspects of a patient's care. This model is designed for patients with severe and persistent illness who need more support than standard outpatient services provide.

Treatment Adherence and Recovery

Challenges of treatment adherence

Treatment non-adherence is one of the biggest obstacles in managing schizophrenia. Research estimates that roughly 50% of patients stop taking their medication within the first year. This matters because stopping antipsychotics dramatically increases the risk of relapse.

Several factors contribute to non-adherence:

• Anosognosia (lack of insight into the illness): Many patients genuinely don't believe they are sick, which makes taking medication feel pointless
• Side effects: Weight gain, sedation, and movement problems can feel worse than the illness itself to some patients
• Cognitive impairments: Memory and executive function deficits can make it hard to follow a medication schedule
• Substance abuse: Co-occurring substance use disorders interfere with treatment engagement
• Inadequate social support: Patients without stable housing or supportive relationships have fewer resources to maintain treatment

Strategies to improve adherence:

1. Provide psychoeducation for both patients and families about the illness and why ongoing treatment matters
2. Simplify regimens by using long-acting injectable (LAI) antipsychotics, which are given every 2–4 weeks and remove the need for daily pills
3. Actively monitor and manage side effects so patients aren't forced to choose between symptom relief and quality of life
4. Build a strong therapeutic alliance between patients and providers, since trust is a major predictor of adherence
5. Use practical tools like medication reminders, pill organizers, or phone apps
6. Treat co-occurring substance use disorders directly rather than ignoring them

Recovery concept in schizophrenia

Recovery in schizophrenia means more than just reducing symptoms. The modern recovery model emphasizes achieving personal goals, improving quality of life, and regaining a sense of purpose. It centers on hope, empowerment, and self-determination rather than defining success purely by clinical measures.

Factors that contribute to positive recovery outcomes:

• Early identification and intervention: Programs that catch first-episode psychosis early and provide coordinated care (like the RAISE model in the U.S.) show significantly better long-term outcomes
• Optimal pharmacological treatment with careful attention to side effect management
• Active engagement in psychosocial interventions (CBT, social skills training, vocational rehab)
• A strong therapeutic alliance with healthcare providers
• Family and social support networks
• Access to comprehensive, coordinated, and continuous care
• Opportunities for meaningful social and occupational activities
• Treatment of co-occurring medical conditions and substance use disorders
• Attention to physical health, since patients with schizophrenia have a life expectancy roughly 15–20 years shorter than the general population, largely due to cardiovascular disease and metabolic conditions